Design of Potent and Proteolytically Stable Oxyntomodulin Analogs. 2016

Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
California Institute for Biomedical Research (Calibr) , 11119 North Torrey Pines Road, La Jolla, California 92037, United States.

Incretin-based peptides are effective therapeutics for treating type 2 diabetes mellitus (T2DM). Oxyntomodulin (OXM), a dual agonist of GLP-1R and GCGR, has shown superior weight loss and glucose lowering effects, compared to single GLP-1R agonists. To overcome the short half-life and rapid renal clearance of OXM, which limit its therapeutic potential, both lipid and PEG modified OXM analogs have been reported. However, these approaches often result in reduced potency or PEG-associated toxicity. Herein, we report a new class of cross-linked OXM analogs that show increased plasma stability and higher potency in activating both GLP-1R and GCGR. Moreover, the extended in vivo half-life results in superior antihyperglycemic activity in mice compared to the wild-type OXM.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D003432 Cross-Linking Reagents Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. Bifunctional Reagent,Bifunctional Reagents,Cross Linking Reagent,Crosslinking Reagent,Cross Linking Reagents,Crosslinking Reagents,Linking Reagent, Cross,Linking Reagents, Cross,Reagent, Bifunctional,Reagent, Cross Linking,Reagent, Crosslinking,Reagents, Bifunctional,Reagents, Cross Linking,Reagents, Cross-Linking,Reagents, Crosslinking
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067757 Glucagon-Like Peptide-1 Receptor A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS). GLP-1 Receptor,GLP-1R Receptor,GLP1R Protein,GLP1R Receptor,GLP 1 Receptor,GLP 1R Receptor,Glucagon Like Peptide 1 Receptor,Peptide-1 Receptor, Glucagon-Like,Protein, GLP1R,Receptor, GLP-1,Receptor, GLP-1R,Receptor, GLP1R,Receptor, Glucagon-Like Peptide-1
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D053772 Oxyntomodulin A 37-amino acid peptide derived from the C-terminal of GLICENTIN. It is mainly produced by the INTESTINAL L CELLS. Oxyntomodulin can reduce digestive secretions, delay gastric emptying, and reduced food intake. Glicentin (33-69),Proglucagon (33-69)

Related Publications

Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
May 2022, ACS chemical biology,
Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
January 2019, Tetrahedron,
Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
January 2018, European journal of medicinal chemistry,
Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
December 2018, Journal of medicinal chemistry,
Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
January 2008, Angewandte Chemie (International ed. in English),
Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
December 2023, Bioorganic & medicinal chemistry letters,
Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
January 1985, Regulatory peptides. Supplement,
Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
January 2017, Methods in molecular biology (Clifton, N.J.),
Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
September 2012, Journal of the American Chemical Society,
Avinash Muppidi, and Huafei Zou, and Peng Yu Yang, and Elizabeth Chao, and Lance Sherwood, and Vanessa Nunez, and Ashley K Woods, and Peter G Schultz, and Qing Lin, and Weijun Shen
July 1997, Nature biotechnology,
Copied contents to your clipboard!